Buprenorphine for Chronic Pain Management: a Narrative Review
Purpose of Review The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine. Recent Findings Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions. Summary Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Current Review of Pain - 27(2023), 12 vom: 28. Okt., Seite 811-820 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vu, Peter D. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Buprenorphine |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11916-023-01185-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054423368 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054423368 | ||
| 003 | DE-627 | ||
| 005 | 20240118064706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-023-01185-4 |2 doi | |
| 035 | |a (DE-627)SPR054423368 | ||
| 035 | |a (SPR)s11916-023-01185-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vu, Peter D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Buprenorphine for Chronic Pain Management: a Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine. Recent Findings Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions. Summary Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD. | ||
| 650 | 4 | |a Buprenorphine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chronic pain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Opioids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chronic opioid therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Opioid use disorder |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bansal, Vishal |4 aut | |
| 700 | 1 | |a Chitneni, Ahish |4 aut | |
| 700 | 1 | |a Robinson, Christopher L. |4 aut | |
| 700 | 1 | |a Viswanath, Omar |4 aut | |
| 700 | 1 | |a Urits, Ivan |4 aut | |
| 700 | 1 | |a Kaye, Alan D. |4 aut | |
| 700 | 1 | |a Nguyen, Anvinh |4 aut | |
| 700 | 1 | |a Govindaraj, Ranganathan |4 aut | |
| 700 | 1 | |a Chen, Grant H. |4 aut | |
| 700 | 1 | |a Hasoon, Jamal |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 27(2023), 12 vom: 28. Okt., Seite 811-820 |w (DE-627)SPR023001666 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:12 |g day:28 |g month:10 |g pages:811-820 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-023-01185-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 12 |b 28 |c 10 |h 811-820 | ||